Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia

Siyi Li1,2, Qingjie Xin1,2, Yan Yan1,2

  • 1Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; and.

Insights

Phosphodiesterase 5 (Pde5) inhibition reduces blood pressure and protects organs from damage caused by chronic intermittent hypoxia (CIH). This suggests Pde5 plays a key role in CIH-induced injury, potentially via oxidative stress pathways.

Area of Science:

  • Cardiovascular Research
  • Sleep Medicine
  • Pharmacology

Background:

  • Obstructive sleep apnea (OSA) is linked to cardiovascular complications.
  • The role of phosphodiesterase 5 (Pde5) in OSA-induced organ damage is not well understood.
  • Chronic intermittent hypoxia (CIH) is a key feature of OSA.

Purpose of the Study:

  • To investigate the role of Pde5 in a mouse model of CIH.
  • To determine if Pde5 inhibition mitigates CIH-induced damage.

Main Methods:

  • Utilized C57BL/6J wild-type (WT) and Pde5 knockout (Pde5-/-) mice exposed to CIH or room air (RA).
  • Administered sildenafil (a Pde5 inhibitor) or saline to WT mice under CIH.
  • Assessed blood pressure, cardiac function (echocardiography), organ physical indicators, histopathology (cardiomyocyte size, fibrosis), and serum markers (cGMP, MDA).

Main Results:

  • CIH increased blood pressure, altered heart structure, and decreased cGMP in WT mice.
  • Pde5-/- mice and sildenafil treatment reduced systolic blood pressure and attenuated target organ damage (heart, kidney) in CIH.
  • Pde5 inhibition decreased malondialdehyde levels and markers of inflammation and oxidative stress.

Conclusions:

  • Pde5 inhibition effectively reduces blood pressure and alleviates target organ damage in a CIH model.
  • The protective effects of Pde5 inhibition in CIH may be mediated through the modulation of oxidative stress.
  • Targeting Pde5 represents a potential therapeutic strategy for managing CIH-related complications.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
229
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
189
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
537
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
1.1K